Sometimes even the experts need a little help staying holly and jolly. Research shows holiday season stress can feel insurmountable. No one is immune. Mental health professionals, who are usually helping others manage emotions, put their own advice into practice as the year winds down.
Boehringer Ingelheim has initiated GioTag, a real-world study to assess the impact of sequential therapy in patients with EGFR mutation-positive (M+) advanced non-small cell lung cancer (NSCLC). Data from approximately 190 patients who received tyrosine kinase inhibitors (TKI) – afatinib* in first-line, followed by second-line osimertinib**as part of standard clinical practice – will be analysed to determine total time on treatment.
The U.S. Food and Drug Administration(FDA) expanded the approved use of Nucala (mepolizumab) to treat adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease that causes vasculitis, an inflammation in the wall of blood vessels of the body. This new indication provides the first FDA-approved therapy specifically to treat EGPA.
SwipeSense, a Chicago-based healthcare technology company has raised a $10.6 million in Series B2 funding led by Eclipse Ventures, with participation from Sandbox Industries and other existing technology and healthcare investors. The company plans to utilize the funding to improve its location-aware apps for healthcare platform, explore new use cases and expand its growing team.
LSP has raised $330 million for its second medical technology fund. The big jump in size over the first fund tees up LSP to place bets on 15 companies with close-to-market devices, diagnostics and digital health tools.
The final FDA guidance on design consideration and pre-market submission for interoperable medical devices was released on September 6. The demand for these devices is increasing in the healthcare system as our dependence on more rapid and protected interactions between devices grows. This increase presents a need for a parallel increase in adequate FDA regulations for this elaborate device field.
Approval based on data from the Phase III RESORCE study where Stivarga® (regorafenib) demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar® (sorafenib)
Contrary to popular belief, and the opinions of many women, men really do suffer from 'man flu,' at least according to a Canadian researcher and his most recent study.
A DNA double helix is seen in an undated artist's illustration released by the National Human Genome Research Institute to Reuters on May 15, 2012. REUTERS/National Human Genome Research Institute/Handout.
The team has unveiled a neural stimulator that is less than a cubic millimeter in size that can be placed directly where desired and that is powered using an external induction-based system.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.